Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.41 |
| ▸ | CDK2 | P24941 | 5/20 | 0.40 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.39 |
| ▸ | PTP4A2 | Q12974 | 1/20 | 0.39 |
| ▸ | PTP4A1 | Q93096 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 8/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | HTR1B | P28222 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21963461 | 0.80 | PTP4A3 (0.47) | GSK3BCDK2PTP4A3PTP4A2PTP4A1 | |
| SCHEMBL21963445 | 0.78 | PTP4A3 (0.63) | GSK3BCDK2PTP4A3PTP4A2PTP4A1 | |
| SCHEMBL21963437 | 0.75 | ELANE (0.42) | MAPTELANENPC1ALDH1A1HPGD | |
| SCHEMBL31484430 | 0.68 | KDM4E (0.50) | GSK3BPTP4A3PTP4A2PTP4A1MAPT | |
| SCHEMBL4941164 | 0.65 | ELANE (0.61) | MAPTELANEALDH1A1SMN1; SMN2 | |
| SCHEMBL7775891 | 0.64 | CA2 (0.61) | ELANE | |
| SCHEMBL13998362 | 0.64 | ELANE (0.76) | ELANE | |
| SCHEMBL6036166 | 0.64 | ELANE (0.47) | MAPTELANERAB9A | |
| SCHEMBL7256004 | 0.64 | GAA (0.49) | MAPTELANEALDH1A1 | |
| SCHEMBL26343191 | 0.63 | DTYMK (0.50) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12227515-B2 | In-flow photooxygenation of aminothienopyridinones generates novel PTP4A3 phosphatase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-02-18 | — | — | US | disclosed |
| US-12202839-B2 | In-flow photooxygenation of aminothienopyridinones generates PTP4A3 phosphatase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-01-21 | — | — | US | disclosed |
| US-20220017534-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | UNITED STATES GOVERNMENT | 2022-01-20 | — | — | US | disclosed |
| US-20210395266-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | UNITED STATES GOVERNMENT | 2021-12-23 | — | — | US | disclosed |
| EP-3880200-A2 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | University of Virginia Patent Foundation (US) | 2021-09-22 | — | — | EP | disclosed |
| EP-3880684-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | University of Virginia Patent Foundation (US) | 2021-09-22 | — | — | EP | disclosed |
| WO-2020102243-A2 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020102245-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017534-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | PTP4A3, PTPRC, PTPRF | GSK3B 481/4885CDK2 283/4885PTP4A3 1/4885 |
| US-12202839-B2 | In-flow photooxygenation of aminothienopyridinones generates PTP4A3 phosphatase inhibitors | PTP4A3, PTPRO, PTPRC | GSK3B 454/4885CDK2 400/4885PTP4A3 1/4885 |
| US-20210395266-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | PTP4A3, PTPRO, PTPRC | GSK3B 418/4885CDK2 385/4885PTP4A3 1/4885 |
| US-12227515-B2 | In-flow photooxygenation of aminothienopyridinones generates novel PTP4A3 phosphatase inhibitors | PTP4A3, PTPRC, PTPRF | GSK3B 481/4885CDK2 283/4885PTP4A3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.